Compugen to Present at 2026 Stifel Virtual Oncology Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy CGEN?
Source: PRnewswire
- Forum Presentation Scheduled: Compugen Ltd. will present at the 2026 Stifel Virtual Oncology Forum on May 19, 2026, from 10:00 to 10:25 AM ET, showcasing its latest advancements in cancer immunotherapy, which is expected to attract attention from investors and industry experts.
- Innovative Platform Overview: Utilizing its AI/ML-powered Unigen™ computational discovery platform, Compugen is focused on identifying novel drug targets and developing cancer immunotherapies, highlighting its four clinical-stage programs, including COM701 and COM902, which possess significant market potential.
- Clinical Trial Progress: Compugen is currently conducting the MAIA-ovarian trial, evaluating COM701 as a single agent in maintenance therapy for relapsed platinum-sensitive ovarian cancer, and if successful, it will provide new treatment options for patients, enhancing the company's influence in oncology.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig, a PD-1/TIGIT bispecific antibody, is undergoing multiple clinical trials, and positive results could further solidify Compugen's position in the cancer treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGEN
Wall Street analysts forecast CGEN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.030
Low
4.00
Averages
4.00
High
4.00
Current: 3.030
Low
4.00
Averages
4.00
High
4.00
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compugen to Present at 2026 Stifel Virtual Oncology Forum
- Forum Presentation Scheduled: Compugen Ltd. will present at the 2026 Stifel Virtual Oncology Forum on May 19, 2026, from 10:00 to 10:25 AM ET, showcasing its latest advancements in cancer immunotherapy, which is expected to attract attention from investors and industry experts.
- Innovative Platform Overview: Utilizing its AI/ML-powered Unigen™ computational discovery platform, Compugen is focused on identifying novel drug targets and developing cancer immunotherapies, highlighting its four clinical-stage programs, including COM701 and COM902, which possess significant market potential.
- Clinical Trial Progress: Compugen is currently conducting the MAIA-ovarian trial, evaluating COM701 as a single agent in maintenance therapy for relapsed platinum-sensitive ovarian cancer, and if successful, it will provide new treatment options for patients, enhancing the company's influence in oncology.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig, a PD-1/TIGIT bispecific antibody, is undergoing multiple clinical trials, and positive results could further solidify Compugen's position in the cancer treatment market.
See More
Compugen to Release Q1 2026 Financial Results on May 18
- Earnings Release Schedule: Compugen will announce its Q1 2026 financial results on May 18 before U.S. markets open, with management hosting a conference call and webcast at 8:30 AM ET to provide updates on corporate performance and financial results.
- Clinical Trial Progress: The ongoing MAIA-ovarian trial evaluates COM701 as a single agent for maintenance therapy in relapsed platinum-sensitive ovarian cancer, reflecting the company's commitment to advancing cancer immunotherapy research.
- Collaborative Development Projects: Under an exclusive licensing agreement with AstraZeneca, Compugen's PD-1/TIGIT bispecific antibody rilvegostomig is undergoing multiple clinical trials, indicating a strategic partnership approach to developing new therapies with major pharmaceutical companies.
- Innovative Drug Pipeline: Compugen's immuno-oncology pipeline features four clinical-stage programs, including potential first-in-class and best-in-class antibodies, showcasing the company's leadership in utilizing AI/ML technologies for novel drug target discovery.
See More
Compugen to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Schedule: Compugen will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45 to 9:25 AM ET, which is expected to enhance the company's visibility in the capital markets by attracting investor and industry expert attention.
- Technology Platform Overview: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, to identify novel drug targets and biological pathways for cancer immunotherapy, showcasing the company's innovative capabilities and technological advantages in cancer treatment.
- Clinical Progress Update: Compugen's COM902 anti-TIGIT antibody is currently in Phase 1 development, while rilvegostomig is in Phase 3 development under AstraZeneca, indicating the company's active progress in clinical trials and potential for collaboration.
- Diverse Pipeline Strategy: Compugen's early-stage immuno-oncology projects include potential first-in-class antibodies like COM701 and GS-0321, reflecting the company's strategic positioning and market prospects in developing new mechanisms to activate the immune system against cancer.
See More
Compugen Reports 2025 Financial Results and Strategic Update
- Cash Flow Extension: Compugen successfully extended its cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca, enhancing financial stability and ensuring funding for multiple upcoming clinical trials.
- Significant Revenue Growth: The company reported $67.3 million in revenue for Q4 2025, a substantial increase from $1.47 million in Q4 2024, demonstrating significant progress in commercialization, particularly with a $65 million upfront payment from AstraZeneca.
- R&D Expense Optimization: R&D expenses decreased to $22.8 million in 2025 from $24.8 million in 2024, reflecting improved efficiency in clinical trial management while freeing up funds for new projects.
- Net Profit Turnaround: Compugen achieved a net profit of approximately $56.8 million in Q4 2025, a significant improvement from a net loss of $6.1 million in Q4 2024, indicating a marked enhancement in profitability and boosting investor confidence.
See More
Compugen Q4 Earnings Exceed Expectations with Significant Revenue Growth
- Strong Earnings Report: Compugen's Q4 GAAP EPS of $0.60 surpassed expectations by $0.55, indicating a significant improvement in profitability and reflecting the success of its business model.
- Revenue Surge: The company reported revenue of $67.33 million, a staggering 4480.3% year-over-year increase, exceeding market expectations by $53.03 million, demonstrating robust demand for its products and services.
- Healthy Cash Flow: As of December 31, 2025, Compugen had approximately $145.6 million in cash, cash equivalents, short-term bank deposits, and marketable securities, ensuring sufficient funding for its operational plans through 2029, supporting its long-term growth strategy.
- Debt-Free Position: The cash balance includes a $65 million upfront payment from AstraZeneca, and with no debt, Compugen is well-positioned for future investments and expansion, providing a solid financial foundation for growth.
See More
Compugen Set to Announce Q4 Earnings on March 2nd
- Earnings Announcement: Compugen is set to release its Q4 earnings on March 2nd before market open, with a consensus EPS estimate of $0.14, reflecting a substantial year-over-year increase of 300%, indicating a significant improvement in profitability.
- Revenue Surge: Analysts project that Compugen's Q4 revenue will reach $14.3 million, representing an impressive year-over-year growth of 872.8%, which suggests a strong sales momentum in the market that could attract more investor interest.
- Historical Performance: Over the past two years, Compugen has beaten EPS estimates 88% of the time and revenue estimates 38% of the time, enhancing market confidence in its future financial performance due to this consistent track record of exceeding expectations.
- Royalty Deal Impact: Compugen's recent royalty agreement with AstraZeneca has led to a rise in its stock price, further solidifying its market position in the biopharmaceutical sector and potentially supporting future revenue growth.
See More
Compugen to Present at 2026 Stifel Virtual Oncology Forum
- Forum Presentation Scheduled: Compugen Ltd. will present at the 2026 Stifel Virtual Oncology Forum on May 19, 2026, from 10:00 to 10:25 AM ET, showcasing its latest advancements in cancer immunotherapy, which is expected to attract attention from investors and industry experts.
- Innovative Platform Overview: Utilizing its AI/ML-powered Unigen™ computational discovery platform, Compugen is focused on identifying novel drug targets and developing cancer immunotherapies, highlighting its four clinical-stage programs, including COM701 and COM902, which possess significant market potential.
- Clinical Trial Progress: Compugen is currently conducting the MAIA-ovarian trial, evaluating COM701 as a single agent in maintenance therapy for relapsed platinum-sensitive ovarian cancer, and if successful, it will provide new treatment options for patients, enhancing the company's influence in oncology.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig, a PD-1/TIGIT bispecific antibody, is undergoing multiple clinical trials, and positive results could further solidify Compugen's position in the cancer treatment market.
See More
Compugen to Release Q1 2026 Financial Results on May 18
- Earnings Release Schedule: Compugen will announce its Q1 2026 financial results on May 18 before U.S. markets open, with management hosting a conference call and webcast at 8:30 AM ET to provide updates on corporate performance and financial results.
- Clinical Trial Progress: The ongoing MAIA-ovarian trial evaluates COM701 as a single agent for maintenance therapy in relapsed platinum-sensitive ovarian cancer, reflecting the company's commitment to advancing cancer immunotherapy research.
- Collaborative Development Projects: Under an exclusive licensing agreement with AstraZeneca, Compugen's PD-1/TIGIT bispecific antibody rilvegostomig is undergoing multiple clinical trials, indicating a strategic partnership approach to developing new therapies with major pharmaceutical companies.
- Innovative Drug Pipeline: Compugen's immuno-oncology pipeline features four clinical-stage programs, including potential first-in-class and best-in-class antibodies, showcasing the company's leadership in utilizing AI/ML technologies for novel drug target discovery.
See More
Compugen to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Schedule: Compugen will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45 to 9:25 AM ET, which is expected to enhance the company's visibility in the capital markets by attracting investor and industry expert attention.
- Technology Platform Overview: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, to identify novel drug targets and biological pathways for cancer immunotherapy, showcasing the company's innovative capabilities and technological advantages in cancer treatment.
- Clinical Progress Update: Compugen's COM902 anti-TIGIT antibody is currently in Phase 1 development, while rilvegostomig is in Phase 3 development under AstraZeneca, indicating the company's active progress in clinical trials and potential for collaboration.
- Diverse Pipeline Strategy: Compugen's early-stage immuno-oncology projects include potential first-in-class antibodies like COM701 and GS-0321, reflecting the company's strategic positioning and market prospects in developing new mechanisms to activate the immune system against cancer.
See More
Compugen Reports 2025 Financial Results and Strategic Update
- Cash Flow Extension: Compugen successfully extended its cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca, enhancing financial stability and ensuring funding for multiple upcoming clinical trials.
- Significant Revenue Growth: The company reported $67.3 million in revenue for Q4 2025, a substantial increase from $1.47 million in Q4 2024, demonstrating significant progress in commercialization, particularly with a $65 million upfront payment from AstraZeneca.
- R&D Expense Optimization: R&D expenses decreased to $22.8 million in 2025 from $24.8 million in 2024, reflecting improved efficiency in clinical trial management while freeing up funds for new projects.
- Net Profit Turnaround: Compugen achieved a net profit of approximately $56.8 million in Q4 2025, a significant improvement from a net loss of $6.1 million in Q4 2024, indicating a marked enhancement in profitability and boosting investor confidence.
See More
Compugen Q4 Earnings Exceed Expectations with Significant Revenue Growth
- Strong Earnings Report: Compugen's Q4 GAAP EPS of $0.60 surpassed expectations by $0.55, indicating a significant improvement in profitability and reflecting the success of its business model.
- Revenue Surge: The company reported revenue of $67.33 million, a staggering 4480.3% year-over-year increase, exceeding market expectations by $53.03 million, demonstrating robust demand for its products and services.
- Healthy Cash Flow: As of December 31, 2025, Compugen had approximately $145.6 million in cash, cash equivalents, short-term bank deposits, and marketable securities, ensuring sufficient funding for its operational plans through 2029, supporting its long-term growth strategy.
- Debt-Free Position: The cash balance includes a $65 million upfront payment from AstraZeneca, and with no debt, Compugen is well-positioned for future investments and expansion, providing a solid financial foundation for growth.
See More
Compugen Set to Announce Q4 Earnings on March 2nd
- Earnings Announcement: Compugen is set to release its Q4 earnings on March 2nd before market open, with a consensus EPS estimate of $0.14, reflecting a substantial year-over-year increase of 300%, indicating a significant improvement in profitability.
- Revenue Surge: Analysts project that Compugen's Q4 revenue will reach $14.3 million, representing an impressive year-over-year growth of 872.8%, which suggests a strong sales momentum in the market that could attract more investor interest.
- Historical Performance: Over the past two years, Compugen has beaten EPS estimates 88% of the time and revenue estimates 38% of the time, enhancing market confidence in its future financial performance due to this consistent track record of exceeding expectations.
- Royalty Deal Impact: Compugen's recent royalty agreement with AstraZeneca has led to a rise in its stock price, further solidifying its market position in the biopharmaceutical sector and potentially supporting future revenue growth.
See More
